Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BMB-101,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Bright Minds Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Firefly Neuroscience Collaborates with Bright Minds for AI-Based Study
Details : The collaboration aims to analyze the data from its first-in-human Phase 1 of BMB-101, a highly selective 5-HT2C, Gq-protein biased agonist, for neuropsychiatric disorders and epilepsy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2024
Lead Product(s) : BMB-101,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Bright Minds Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SP-624,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Arrivo BioVentures
Deal Size : Inapplicable
Deal Type : Inapplicable
Firefly Neuroscience Uses Brain Analytics Platform in Phase 1 SP-624 Study
Details : SP-624 is a first-in-class SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of patients with major depressive disorder.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : SP-624,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Arrivo BioVentures
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Stalicla
Deal Size : Undisclosed
Deal Type : Partnership
Details : STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candi...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Ibudilast,Bumetanide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Stalicla
Deal Size : Undisclosed
Deal Type : Partnership